Pfizer and BioNTech to Supply EU with up to 200M Doses of BNT162B2 Against COVID-19
Shots:
- The companies sign an agreement with the EC to supply 200M doses of BNT162b2 mRNA-based vaccine candidate against SARS-CoV-2 to EU member states- with an option to request an additional 100M doses
- Deliveries are anticipated to start by the end of 2020- following clinical success and regulatory authorization. The companies expect to produce ~1.3B doses in 2021 globally
- Pfizer and BioNTech initiated a rolling submission to the EMA in Oct’2020 and will continue a regular and open dialogue with the EMA providing results from their ongoing P-III study
Ref: Pfizer | Image: MedPage Today
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com